Search Results 181-190 of 16090 for Conduction

1. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer - Mayo Clinic

   Symptomatic congestive heart failure (i.e., Grade 2 or higher), history or current evidence of clinically significant cardiac arrhythmia and/or conduction ...

2. A Study to Evaluate the Effect of Olorinab on Gastrointestinal Transit in Patients with Irritable Bowel Syndrome - Mayo Clinic

   ... conduction abnormalities. Clinically significant cardiac history or presence of ECG findings as judged by the Investigator or qualified designee at ...

3. Heart arrhythmia - Symptoms and causes - Mayo Clinic

   Conduction block. A block of the heart's electrical pathways can cause the signals that trigger the heartbeats to slow down or stop. Some blocks may cause ...

4. A Clinical Study To Test How Effective And Safe GLPG1690 Is For Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard Medical Treatment

   Clinically significant abnormalities detected on ECG of either rhythm or conduction, a QTcF > 450 ms, or a known long QT syndrome. Currently taking ...

5. A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma - Mayo Clinic

   History or presence of clinically significant ventricular arrhythmias, atrial fibrillation, resting bradycardia, or conduction abnormality;; Unstable angina ...

6. A Study Comparing Combinations of Chemotherapy for Treating Women who have Undergone Surgery for Node-Positive Breast Cancer - Mayo Clinic

   Severe conduction abnormality; Valvular disease with documented cardiac function compromise; Uncontrolled hypertension defined as blood pressure greater than ...

7. Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma - Mayo Clinic

   Persistent or uncontrolled ventricular arrhythmias or atrial fibrillation or cardiac conduction abnormalities not mitigated by a pacemaker. Subject had ...

8. A Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard Medical Treatment - Mayo Clinic

   Clinically significant abnormalities detected on ECG of either rhythm or conduction, a QTcF > 450 ms, or a known long QT syndrome. Patients with implantable ...

9. Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer - Mayo Clinic

   Symptomatic chronic heart failure history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality < 6 months prior to ...

10. A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor - Mayo Clinic

    Angina pectoris requiring anti-anginal medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or ...